BSR_David - A frequent poster on this board, HPTAXIS, has claimed on iHub that your subscription research service recently provided information to subscribers on specific trial details relating to surgical procedures, number of dropouts and incidence of adverse events in a clinical trial being run by Repros Therapeutics. This important and clearly material information has not been provided to investors by Repros in press releases, SEC filings or on conference calls.
Are HPTAXIS' claims true? If so, can you please explain to me how this is NOT a clear breach of the SEC's Regulation Fair Disclosure by the company?
Market Data 
Markets 
AI
